Genus is buying back shares under a new £60m programme after full-year profit jumped and net Debt fell sharply, helped by a gain on its Chinese pig genetics joint venture.

Genus (LSE:GNS), the FTSE 250 animal genetics specialist, has been executing a share buyback since September, with weekly transaction notices including one on 5 October. The programme follows a set of full-year results that showed a marked improvement in profitability and a much firmer balance sheet, giving management room to return Capital while continuing to commercialise its gene-edited pig technology.

Profit up despite softer revenue

For the year to 30 June 2026, published on 10 September, Genus reported Revenue of £658.1m, down 2% on the prior year. Adjusted profit before tax, however, rose 35% to £100.2m, or 30% in constant currency. Statutory profit before tax was much higher, at £310.5m, reflecting a £204.1m gain linked to the PIC China joint venture.

Adjusted Basic Earnings Per Share increased to 110.3p from 81.8p, and the board proposed a final Dividend of 24.0p, taking the full-year payout to 35.2p, up 10%. Net debt fell to £71.8m from £228.2m a year earlier, cutting Leverage to just 0.4 times.

The pig genetics business, PIC, delivered revenue of £355.8m, with adjusted operating profit including joint ventures rising 17% to £130.8m. Total volumes grew 12%, and the result included a milestone payment of £5.6m. The bovine division, ABS, reported revenue of £299.8m and a 17% rise in adjusted operating profit to £22.9m, which the company attributed to savings from its Value Acceleration Programme.

The improvement in profitability, despite lower revenue, points to the effect of cost discipline and a better mix across both divisions. It also reflects the contribution from joint ventures, which form an important part of PIC's international footprint. The sharp fall in net debt has left the Balance Sheet with considerably more flexibility than a year ago.

Capital returns and outlook

Alongside the results, Genus launched a £60m share buyback, to be completed during the current financial year. Chief executive Jorgen Kokke described the year as a solid performance for the group.

For the year to June 2027, the company expects adjusted profit before tax in constant currency to be in line with consensus, which it cited at an average of about £93.0m, and moderately above normalised 2026 adjusted profit of £90.3m. Profit is expected to be weighted towards the second half. The difference between the reported and normalised figures reflects one-off items in the year just ended.

Gene editing remains the long-term catalyst

Investor interest in Genus continues to centre on its PRRS-resistant pig, known as PRP, which uses gene editing to protect animals against porcine reproductive and respiratory syndrome, one of the most costly diseases in pork production. The company has secured approvals or favourable determinations in Argentina, Canada, Uruguay and Peru and has begun commercialisation in selected Latin American countries. It is continuing to pursue approvals in Mexico, Japan and China, which are important export markets for pork producers and therefore influence the speed of wider adoption.

The company's results also depend on conditions in global protein markets, including pork prices and producer profitability, which shape Demand for premium genetics. Exposure to China, where hog prices have been volatile, has historically been a cause of earnings variability for PIC.

For FTSE 250 investors, the main points to watch will be progress on regulatory approvals for PRP, the pace of the buyback and the trajectory of ABS margins as cost savings continue to bed in across the bovine business.